Understanding IL-23s Role and Immune Targets in Peripheral and Axial Spondyloarthritis A Study of Immune Responses and Gene Expression in Patients with Spondyloarthritis

What this Trial Is About

Researchers are investigating the role of IL-23 in the development and progression of axial and peripheral spondyloarthritis SpA, including psoriatic arthritis, to better understand how the body responds to anti-IL-23 biologic treatments. This multicenter, non-randomized prospective study focuses on patients attending rheumatology departments in several hospitals and aims to explore the cellular and molecular targets of IL-23 signaling in these chronic inflammatory diseases. Participants are divided into two groups those with axial SpA and those with peripheral SpA or psoriatic arthritis. The study involves collecting blood samples and, when required as part of standard care, synovial fluid from joint aspirations in peripheral SpA patients. These samples will be used to analyze gene expression, immune cell characteristics, and cytokine production related to IL-23 and IL-17 pathways over a period of up to four years. Throughout the study, participants will undergo assessments including profiling of chromatin regions, transcriptome and genome analysis, cytokine expression monitoring, and single cell transcriptome analysis. The research will also measure lymphocyte levels to observe immune responses to anti-IL-23 treatments. Participants involvement includes laboratory tests and sample collections aligned with routine care, with the study concluding by September 2027.

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis